KRAS and non-small cell lung carcinoma: Sotorasib is the first clinically available direct KRAS G12C inhibitor that was FDA-approved for the treatment of locally advanced and metastatic NSCLC harboring the KRAS G12C mutation.90 Adagrasib was later approved as a 2nd-line treatment for metastatic NSCLC with the KRAS G12C mutation.94 Both sotorasib and adagrasib are KRAS OFF-state small-molecule covalent inhibitors that irreversibly bind to the cysteine residue in the mutant KRAS-G12C switch-II pocket, as described earlier.